Results from the Phase II clinical trial (NCT02970942) showed that after 72 weeks, 59% of patients in the 0.4 mg semaglutide group achieved NASH resolution without worsening liver fibrosis , a statistically significant result compared to 17% in the placebo group, meeting the primary clinical endpoint
No other peptide receptor family spans this breadth of research interest simultaneously, which is precisely why synthetic melanocortin agonists have become so important as laboratory research tools
Not every patient that has been treated in this manner has had this degree of improvement, but many have reported at least 25-50% improvement when PTC is included in their treatment when we evaluate them using as objective a tool as we can, a self-evaluation questionnaire
Nutrients go straight into your blood, reaching skin cells at concentrations that oral supplements simply cannot match
Like Ozempic, you can inject Wegovy at any time of day, with or without food